Work

Clinical Pharmacogenetics Implementation Consortium Guidelines for HLA-B Genotype and Abacavir Dosing

Year: 2012

Type: article

Abstract: Human leukocyte antigen B (HLA-B) is responsible for presenting peptides to immune cells and plays a critical role in normal immune recognition of pathogens. A variant allele, HLA-B*57:01, is associated with increased risk of a hypersensitivity reaction to the anti-HIV drug abacavir. In the absence of genetic prescreening, hypersensitivity affects ~6% of patients and can be life-threatening with repeated dosing. We provide recommendations (updated periodically at http://www.pharmkgb.org) for the use of abacavir based on HLA-B genotype.

Source: Clinical Pharmacology & Therapeutics

DOI: 10.1038/clpt.2011.355

Authors: M A Martin, T E Klein, B J Dong, M Pirmohamed, D W Haas, D L Kroetz

Institutions: University of California, San Francisco, Stanford University, University of Liverpool, Vanderbilt University

Language: English

Topic: Drug-Induced Adverse Reactions

Subfield: Pharmacology (medical)

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: National Institutes of Health, National Institute of General Medical Sciences